

ELOQUENT-2 updates represent the longest median FU of an immuno-oncology agent in MM

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Hello, I am Dr. Sagar Lonial from the Winship Cancer Institute at Emory University in Atlanta, Georgia. I am here at ASCO 2017 talking about the ELOQUENT-2 update that I presented at this meeting. ELOQUENT-2 was a randomized phase 3 trial treating patients with either lenalidomide-dexamethasone with or without elotuzumab, in a one to three prior lines of therapy study. It was published 2 years ago in the *New England Journal of Medicine*, demonstrating a significant improvement in overall response rate as well as progression-free survival. What we show at this meeting is a 4 year update on that trial where we are demonstrating, I think quite nicely, that the benefit in terms of progression-free survival continues to hold up at about 30% improvement in PFS. There is no increase or change in the adverse events, and most importantly, we are now showing survival curves with a hazard ratio of about 0.63, although there is no *P*-value available on that hazard ratio at this time. I think in summary what this suggests is that elotuzumab plus lenalidomide and dexamethasone in an early relapsed patient population continues to demonstrate benefit in 4-year follow-up, and that there is not clear statistical improvement but hints at improvement in overall survival, without a significant increase in adverse events. Thank you for listening.